These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1236 related articles for article (PubMed ID: 28543695)

  • 1. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Lim SY; Menzies AM; Rizos H
    Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of molecular alterations with immune response in melanoma.
    Szczepaniak Sloane RA; Gopalakrishnan V; Reddy SM; Zhang X; Reuben A; Wargo JA
    Cancer; 2017 Jun; 123(S11):2130-2142. PubMed ID: 28543700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
    Jarkowski A; Norris L; Trinh VA
    Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New treatment options for metastatic melanoma].
    Tietze JK; Berking C
    Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
    [No Abstract]   [Full Text] [Related]  

  • 5. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.
    Zhou AY; Johnson DB
    Am J Clin Dermatol; 2018 Apr; 19(2):181-193. PubMed ID: 28861871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
    Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
    Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of melanoma therapy: developing new drugs and improving the use of old ones.
    Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V
    Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206
    [No Abstract]   [Full Text] [Related]  

  • 8. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
    Welsh SJ; Rizos H; Scolyer RA; Long GV
    Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecularly targeted therapies for melanoma.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new paradigm of systemic therapies for metastatic melanoma.
    Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
    J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
    Rossi A; Roberto M; Panebianco M; Botticelli A; Mazzuca F; Marchetti P
    Eur J Pharmacol; 2019 Nov; 862():172621. PubMed ID: 31446019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies for cutaneous melanoma.
    Kee D; McArthur G
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.
    Duggan MC; Stiff AR; Bainazar M; Regan K; Olaverria Salavaggione GN; Maharry S; Blachly JS; Krischak M; Walker CJ; Latchana N; Tridandapani S; de la Chapelle A; Eisfeld AK; Carson WE
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9629-9634. PubMed ID: 28827320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
    Van Allen EM; Wagle N; Sucker A; Treacy DJ; Johannessen CM; Goetz EM; Place CS; Taylor-Weiner A; Whittaker S; Kryukov GV; Hodis E; Rosenberg M; McKenna A; Cibulskis K; Farlow D; Zimmer L; Hillen U; Gutzmer R; Goldinger SM; Ugurel S; Gogas HJ; Egberts F; Berking C; Trefzer U; Loquai C; Weide B; Hassel JC; Gabriel SB; Carter SL; Getz G; Garraway LA; Schadendorf D;
    Cancer Discov; 2014 Jan; 4(1):94-109. PubMed ID: 24265153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
    Dean E; Lorigan P
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
    Long GV; Fung C; Menzies AM; Pupo GM; Carlino MS; Hyman J; Shahheydari H; Tembe V; Thompson JF; Saw RP; Howle J; Hayward NK; Johansson P; Scolyer RA; Kefford RF; Rizos H
    Nat Commun; 2014 Dec; 5():5694. PubMed ID: 25452114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
    Jang S; Atkins MB
    Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
    Shi H; Hugo W; Kong X; Hong A; Koya RC; Moriceau G; Chodon T; Guo R; Johnson DB; Dahlman KB; Kelley MC; Kefford RF; Chmielowski B; Glaspy JA; Sosman JA; van Baren N; Long GV; Ribas A; Lo RS
    Cancer Discov; 2014 Jan; 4(1):80-93. PubMed ID: 24265155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.